Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Xiwu Hui"'
Autor:
Huandi Ding, Bing Yao, Lei Ci, Jing Feng, Pingkai Ouyang, Guoguang Chen, Xiwu Hui, Demin Zhou
Publikováno v:
Journal of Immunotherapy. 46:161-169
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c0f0d8db5302325ada7cbd9f1f4568d
https://doi.org/10.1097/cji.0000000000000465
https://doi.org/10.1097/cji.0000000000000465
Autor:
Bing Yao, Xiao Gao, Mo Dan, Can Yuan, Xixin Hu, Zhaopeng Sun, Xiwu Hui, Boning Liu, Pingkai Ouyang, Guoguang Chen
Publikováno v:
The AAPS journal. 24(4)
The main objective of this work was to demonstrate which kind of payload is the suitable choice for antibody-drug conjugates directed to widely expressed tumor-associated antigen. Trop-2 is overexpressed in various solid tumors, but it is also presen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::deda4caf9528468acb46bec8b71931e4
https://pubmed.ncbi.nlm.nih.gov/35624189
https://pubmed.ncbi.nlm.nih.gov/35624189
Autor:
Bing Yao, Di Zhang, Weirong Cao, Gaoqiang Yang, Wenbin Li, Xiwu Hui, Pingkai Ouyang, Guoguang Chen, Boning Liu
Publikováno v:
BioMed research international. 2022
The proposed biosimilar candidate needs to demonstrate biosimilarity with reference products, and the quality target product profile and biosimilarity assessment criteria are prerequisite, which should be based on extensive characterization of the re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ce20cf8e550f7bae58769ad16a24e3c
https://pubmed.ncbi.nlm.nih.gov/35535043
https://pubmed.ncbi.nlm.nih.gov/35535043
Publikováno v:
Sheng wu gong cheng xue bao = Chinese journal of biotechnology. 36(4)
PEGylation is considered one of the most successful techniques to improve the characteristics of protein drugs including to increase the circulating half-life of proteins in blood and to decrease their immunogenicity and antigenicity. One known PEG m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9b7fba5553d3f22828ae52045bf4a297
https://pubmed.ncbi.nlm.nih.gov/32347069
https://pubmed.ncbi.nlm.nih.gov/32347069
Publikováno v:
Sheng wu gong cheng xue bao = Chinese journal of biotechnology. 34(4)
IFN-λ1 is a member of a new family of interferons called type Ⅲ IFNs with similar functions to type ⅠIFNs. Previously we obtained recombinant soluble human rhIFN-λ1 from Pichia pastoris. However, the hyper-glycosylation from P. pastoris brings
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0676dab0394cbb04e1aa56f3214bb149
https://pubmed.ncbi.nlm.nih.gov/29701035
https://pubmed.ncbi.nlm.nih.gov/29701035
Publikováno v:
Cancer Letters. 311:141-151
Interferon (IFN)-λ1, as a newly identified IFN, interacts with the structurally unique IFN-λ1 receptor complex and exhibits antiviral and antiproliferation effects. The major focus of our work was to study the antitumor activities of recombinant hu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f381980bb1300242fc109bd4a6fd7193
https://doi.org/10.1016/j.canlet.2011.07.004
https://doi.org/10.1016/j.canlet.2011.07.004
Autor:
Qinshan Li, Bingren Huang, Xia Yang, Deng Chen, Junwen Zhang, Zhenzhen Fan, Xiwu Hui, Shuo Tian, Xiaoli Ma, Hong Chen
Publikováno v:
FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 28(8)
Hepatocellular carcinoma (HCC) is a common cancer associated with chronic hepatitis B virus (HBV) infection. Conventional interferon-α (IFN-α) and pegylated IFNs (PEG-IFNs) approved for chronic HBV infection treatment can reduce the risk of HCC but
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c404ab68f0f2fd7620669b8bb3f377d2
https://pubmed.ncbi.nlm.nih.gov/24769671
https://pubmed.ncbi.nlm.nih.gov/24769671
Publikováno v:
Journal of cellular biochemistry. 113(11)
IFNλR1 is a member of the class II cytokine receptor family, and it associates with IL-10R2 to form a functional receptor complex, IFNλR. This receptor complex transduces signals from IFNλs (IFNλ1, IFNλ2, and IFNλ3), promoting antiviral and ant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a12cf0a582d407ef024cf9a3410e829
https://pubmed.ncbi.nlm.nih.gov/22644879
https://pubmed.ncbi.nlm.nih.gov/22644879
Autor:
Shuo Tian, Xiwu Hui, Zhenzhen Fan, Qinshan Li, Junwen Zhang, Xia Yang, Xiaoli Ma, Bingren Huang, Deng Chen, Hong Chen
Publikováno v:
FASEB Journal; Aug2014, Vol. 28 Issue 8, p3528-3539, 12p